Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Outcomes in Routine Clinical Practice with Methotrexate-Temozolomide-Rituximab Induction and Modified Etoposide-Cytarabine Consolidation in Newly Diagnosed Primary CNS Lymphoma

Blood (2023) 142 (Supplement 1): 987.

https://doi.org/10.1182/blood-2023-186742

Published: 2023

Journal Articles

Comparison of Various Stem Cell Mobilization Regimens for Multiple Myeloma - a 15-Year Retrospective Institutional Analysis from India

Blood (2023) 142 (Supplement 1): 2225.

https://doi.org/10.1182/blood-2023-182563

Published: 2023

Journal Articles

Molecular Patterns of Resistance in Carbapenem Resistant Organisms Detected in Stool Surveillance Cultures in Patients Undergoing Hematopoietic Cell Transplant

Koustubh Shekar, Akanksha Chichra, Keshav Garg, Sujata Lall, Nishant Jindal, Niket Mantri, Sumeet Mirgh, Lingaraj Nayak, Anant Gokarn, Sachin Punatar, Libin Jacob Mathew, Hari Menon, Vivek Bhat, Navin Khattry

Blood (2023) 142 (Supplement 1): 4918.

https://doi.org/10.1182/blood-2023-184659

Published: 2023

Journal Articles

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Blood (2023) 142 (Supplement 1): 4838.

https://doi.org/10.1182/blood-2023-185507

Published: 2023

Journal Articles

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Blood (2023) 142 (Supplement 1): 6878.

https://doi.org/10.1182/blood-2023-180867

Published: 2023

Journal Articles

Withaferin-a Alleviates Acute Graft Versus Host Disease By Regulating Immune Cell Proliferation, Differentiation and Cytokine Storm Via Inhibition of JAK2-STAT3 Signalling

Vikram Gota, Saurabh Kumar Gupta, Deepshikha Dutta, Kajal Dalvi, Twinkle Khanka, Akanksha Chichra, Sachin Punatar, Anant Gokarn, Sumeet Prakash Mirgh, Nishant Jindal, Prashant R. Tembhare, Syed K Khizer Hasan, Lal Hingorani, Navin Khattry

Blood (2022) 140 (Supplement 1): 12669–12670.

https://doi.org/10.1182/blood-2022-164545

Published: 2022

Journal Articles

Machine Learning Based Prediction of Veno Occlusive Disease Following Allogenic Stem Cell Transplantation

Akash Bhojgaria, Dalia Chakrabarty, Kangrui Wang, Gargi Roy, Jiri Pavlu, Balkrishna Padate, Navin Khattry, Kasturi Sengupta, Pronati Gupta, Sara Panmei, Mihir Das, Danish Ghazali, Pallav Mundra, Joydeep Chakrabartty

Blood (2022) 140 (Supplement 1): 12863.

https://doi.org/10.1182/blood-2022-156064

Published: 2022

Journal Articles

Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

Blood (2022) 140 (Supplement 1): 1135–1136.

https://doi.org/10.1182/blood-2022-165715

Published: 2022

Journal Articles

Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Blood (2022) 140 (Supplement 1): 10332–10334.

https://doi.org/10.1182/blood-2022-166082

Published: 2022

Journal Articles

Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing

Blood (2022) 140 (Supplement 1): 4292–4293.

https://doi.org/10.1182/blood-2022-168598

Published: 2022

Journal Articles

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Blood (2022) 140 (Supplement 1): 205–207.

https://doi.org/10.1182/blood-2022-166452

Published: 2022

Journal Articles

An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies

Blood (2021) 138 (Supplement 1): 309.

https://doi.org/10.1182/blood-2021-152548

Published: 2021

Journal Articles

Comparison of Outcomes of Donor Lymphocyte Infusions with or without Lenalidomide in Patients with Hematological Malignancies Post Allogeneic Transplant

Sachin Punatar, Vinodhini Murugaiyan, Anant Gokarn, MDDM, Akanksha Chichra, DNB, Sumeet Prakash Mirgh, MDDM, Lingaraj Nayak, MD DM, Avinash Bonda, MD DM, Vijay Shirure, MD DM, Bhausaheb Bagal, MD DM, Libin J Mathew, BSc, Sadhana Kannan, MSc, Tapan Saikia, MD, Navin Khattry, MD DM

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-141898

Published: 2020

Journal Articles

Incidence, Risk Factors, and Outcomes of Viral Reactivations in Alternative Donor Haematopoietic Stem Cell Transplant

Vinodhini M, MDDM, Anant Gokarn, MDDM, Sachin Punatar, Sumeet Prakash Mirgh, MDDM, Akanksha Chichra, DNB, Vijay Shirure, MD DM, Avinash Bonda, MD DM, Lingaraj Nayak, MD DM, Bhausaheb Bagal, MD DM, Vivek Bhat, MD, Sanjay Biswas, MD, Sadhana Kannan, MSc, Libin J Mathew, Rachana Tripathi, Shesheer Kumar, Tapan Saikia, MD, Navin Khattry, MD DM

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141751

Published: 2020

Journal Articles

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139847

Published: 2020

Journal Articles

Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing

Nikhil Patkar, MD, Anam Fatima Shaikh, Chinmayee Kakirde, Rakhi Salve, Prasanna Bhanshe, Gaurav Chatterjee, MD, Sweta Rajpal, Swapnali Joshi, Shruti Chaudhary, Rohan Kodgule, Dhanlaxmi Lalit Shetty, PhD, Hasmukh Jain, MD, Bhausaheb Bagal, MD DM, Hari Menon, MD, Navin Khattry, MD DM, Manju Sengar, MD DM, Prashant Tembhare, MD, Papagudi Ganesan Subramanian, MD, Sumeet Gujral, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-143457

Published: 2020

Journal Articles

Real World Experience of Etanercept in Steroid Refractory Acute Graft Versus Host Disease from a Tertiary Cancer Centre in India

Akanksha Chichra, DNB, Sachin Punatar, Anant Gokarn, MDDM, Sumeet Prakash Mirgh, MDDM, Vijay Shirure, MD DM, Vinodhini Murugaiyan, Avinash Bonda, MD DM, Lingaraj Nayak, MD DM, Bhausaheb Bagal, MD DM, Sadhana Kannan, MSc, Libin J Mathew, BSc, Tapan Saikia, MD, Navin Khattry, MD DM

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-141920

Published: 2020

Journal Articles

Pre-Transplant Use of Tyrosine Kinase Inhibitors Increases Risk of Transplant Associated Thrombotic Microangiopathy - a Single Centre Analysis of Incidence, Risk Factors and Outcomes

Siddhesh Arun Kalantri, MD, Akanksha Chichra, DNB, Amit Kumar Agrawal, MDMDcine, Lingaraj Nayak, MDDM MDcal Oncology, Avinash Bonda, MD DM, Sachin Punatar, MBBS,MDDM MDcal Oncology, Anant Gokarn, MD, Bhausaheb Bagal, MD DM, Libin J Mathew, Sadhana Kannan, MSc, Navin Khattry, MD DM MDcal Oncology

Blood (2019) 134 (Supplement_1): 1983.

https://doi.org/10.1182/blood-2019-125029

Published: 2019

Journal Articles

Fludarabine Melphalan Versus Fludarabine Treosulfan As Reduced Intensity Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplant - a Retrospective Analysis

Akanksha Chichra, DNB, Lingaraj Nayak, MDDM MDcal Oncology, Rushabh Kothari, MD DM MDcal Oncology, Siddhesh Arun Kalantri, MD, Avinash Bonda, MD DM, Anant Gokarn, MD, Sachin Punatar, MBBS,MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Sadhana Kannan, MSc, Libin J Mathew, Navin Khattry, MD DM MDcal Oncology

Blood (2019) 134 (Supplement_1): 4493.

https://doi.org/10.1182/blood-2019-128099

Published: 2019

Journal Articles

Efficacy of Artesunate for Treatment of Cytomegalovirus Reactivations in Allogeneic Haematopoietic Stem Cell Transplant Recipients Who Are Intolerant/Unsuitable for Ganciclovir Therapy

Ramnath K Shenoy, MD, Anant Gokarn, MD, Anup Toshniwal, MDDM, Siddhesh Arun Kalantri, MD, Akanksha Chichra, DNB, Sachin Punatar, MBBS,MDDM MDcal Oncology, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Libin J Mathew, Vivek Bhat, MD, Sanjay Biswas, MD, Rohini Kelkar, MD, Navin Khattry, MD DM MDcal Oncology

Blood (2019) 134 (Supplement_1): 4506.

https://doi.org/10.1182/blood-2019-128766

Published: 2019

NARROW

Outcomes in Routine Clinical Practice with Methotrexate-Temozolomide-Rituximab Induction and Modified Etoposide-Cytarabine Consolidation in Newly Diagnosed Primary CNS Lymphoma

Comparison of Various Stem Cell Mobilization Regimens for Multiple Myeloma - a 15-Year Retrospective Institutional Analysis from India

Molecular Patterns of Resistance in Carbapenem Resistant Organisms Detected in Stool Surveillance Cultures in Patients Undergoing Hematopoietic Cell Transplant

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Withaferin-a Alleviates Acute Graft Versus Host Disease By Regulating Immune Cell Proliferation, Differentiation and Cytokine Storm Via Inhibition of JAK2-STAT3 Signalling

Machine Learning Based Prediction of Veno Occlusive Disease Following Allogenic Stem Cell Transplantation

Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Comparison of Outcomes of Donor Lymphocyte Infusions with or without Lenalidomide in Patients with Hematological Malignancies Post Allogeneic Transplant

Incidence, Risk Factors, and Outcomes of Viral Reactivations in Alternative Donor Haematopoietic Stem Cell Transplant

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing

Real World Experience of Etanercept in Steroid Refractory Acute Graft Versus Host Disease from a Tertiary Cancer Centre in India

Pre-Transplant Use of Tyrosine Kinase Inhibitors Increases Risk of Transplant Associated Thrombotic Microangiopathy - a Single Centre Analysis of Incidence, Risk Factors and Outcomes

Fludarabine Melphalan Versus Fludarabine Treosulfan As Reduced Intensity Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplant - a Retrospective Analysis

Efficacy of Artesunate for Treatment of Cytomegalovirus Reactivations in Allogeneic Haematopoietic Stem Cell Transplant Recipients Who Are Intolerant/Unsuitable for Ganciclovir Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only